ArticlePeerJ2017
Octahedral ruthenium (II) polypyridyl complexes as antimicrobial agents against mycobacterium.
Article in PeerJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Interaction of organoruthenium(II)-polypyridyl complexes with DNA and BSA.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022Article
- Antimicrobial Agents Based on Metal Complexes: Present Situation and Future Prospects.International journal of biomaterials · 2022Review
- Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review.Pharmaceutics · 2021Review
- Recent Advances on Octahedral Polypyridyl Ruthenium(II) Complexes as Antimicrobial Agents.Polymers · 2018Review
- The Discovery of an Iridium(III) Dimer Complex as a Potent Antibacterial Agent against Non-Replicating Mycobacterium smegmatis.Polymers · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis is one of the world's deadliest infectious disease with 1.5 millions deaths annually. It is imperative to discover novel compounds with potent activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.